Valuation: Lineage Cell Therapeutics, Inc.

Market Cap 276M 236M 221M 202M 381M 26.4B 385M 2.62B 1.02B 13.25B 1.04B 1.01B 43.85B P/E 2026 *
-16.2x
P/E 2027 * -10.5x
Enterprise Value 276M 236M 221M 202M 381M 26.4B 385M 2.62B 1.02B 13.25B 1.04B 1.01B 43.85B EV / Sales 2026 *
18.1x
EV / Sales 2027 * 16.4x
Free-Float
95.14%
Yield 2026 *
-
Yield 2027 * -
1 day+0.93%
1 week+2.83%
Current month+0.93%
1 month+5.83%
3 months-16.15%
6 months-40.11%
Current year-34.73%
1 week 1.04
Extreme 1.04
1.13
1 month 1
Extreme 1
1.18
Current year 1
Extreme 1
1.98
1 year 1
Extreme 1
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.8
10 years 0.37
Extreme 0.3651
4
Manager TitleAgeSince
Chief Executive Officer 54 2018-09-16
Director of Finance/CFO 50 2022-11-13
Chief Operating Officer - 2010-11-30
Director TitleAgeSince
Director/Board Member 60 2009-06-30
Director/Board Member 68 2014-04-10
Chairman 60 2024-04-26
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Free

Director

125,000 0.0501%
7/1/26
Broadwood Capital, Inc.
FreeCompany 125,000 0.0501%
7/1/26 Free

Director

125,000 0.0501%
Change 5-day change 1-year change 3-year change Capi.($)
+0.93%+2.83%-9.17%-19.26% 276M
+0.94%+4.67%+3.39%+25.12% 51.21B
+1.01%-0.20%+471.68%+564.93% 45.35B
+0.16%+7.88%+36.14%+20.76% 42.84B
-0.66%+2.61%+18.59%+87.04% 42.29B
+0.88%-3.48%+17.20%+53.83% 32.15B
-0.12%+3.84%+33.73%+145.25% 17.31B
-0.53%+1.84% - - 16.55B
+0.52%+5.71%+10.34%+31.83% 14.84B
+1.15%+4.17%+84.49%+50.33% 14.25B
Average +0.43%+3.19%+74.04%+106.65% 27.71B
Weighted average by Cap. +0.41%+3.07%+101.30%+141.66%

Financials

2026 *2027 *
Net sales 15.19M 13.02M 12.18M 11.14M 21.01M 1.45B 21.24M 144M 56.05M 731M 57.05M 55.81M 2.42B 16.83M 14.43M 13.5M 12.34M 23.29M 1.61B 23.53M 160M 62.1M 809M 63.21M 61.84M 2.68B
Net income -22.64M -19.4M -18.15M -16.59M -31.32M -2.17B -31.65M -215M -83.52M -1.09B -85.01M -83.17M -3.6B -34.44M -29.51M -27.61M -25.24M -47.64M -3.3B -48.14M -327M -127M -1.66B -129M -127M -5.48B
Net Debt - -
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
26-08-24 $1.090 +0.93% 607,680
26-08-21 $1.080 0.00% 716,424
26-08-20 $1.080 -1.82% 1,474,329
26-08-19 $1.100 +3.77% 951,490
26-08-18 $1.060 0.00% 1,112,362
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.090USD
Average target price
5.500USD
Spread / Average Target
+404.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LCTX Stock